N-(2-chloropyrimidin-4-yl)-2,3-dimethylindazol-6-amine

We are N-(2-chloropyrimidin-4-yl)-2,3-dimethylindazol-6-amine CAS:444731-74-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: N-(2-chloropyrimidin-4-yl)-2,3-dimethylindazol-6-amine
CAS.NO: 444731-74-2
Synonyms:
N-(2-chloro-4-pyrimidinyl)-2,3-dimethyl-2H-indazol-6-amine
N-(2-CHLOROPYRIMIDIN-4-YL)-2,3-DIMETHYL-2H-INDAZOL-6-AMINE
2H-Indazol-6-amine,N-(2-chloro-4-pyrimidinyl)-2,3-dimethyl

Molecular Formula: C13H12ClN5
Molecular Weight: 273.72100

Physical and Chemical Properties:
Density: 1.414g/cm3
Boiling point:549.991ºC at 760 mmHg
Melting point: /
Flash point: 286.424ºC
Refractive index: 1.705

Specification:
Appearance:White rystalline powder
Purity:≥99%
Total Impurity:1.0% Max.
LOD:1.0% Max.

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Pazopanib hydrochloride CAS:635702-64-6

Related News: According to the business type, it can be divided into non-CMO business of APIs and intermediates and CMO business of APIs and intermediates. 2,6-dimetilfenol CAS:576-26-1 ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.trifluoromethanesulfinyl chloride Once they have decided how to make the compound, our staff in the production department manufacture a high quantity of APIs using the large reactors in our plant.18171-19-2 Once they have decided how to make the compound, our staff in the production department manufacture a high quantity of APIs using the large reactors in our plant.Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.